Dubai, Feb. 8, 2024— Smart Cells International (SCI), a leading member of FamiCord Group, proudly declares Dubai as its GCC hub for stem cell banking, solidifying its commitment to advancing healthcare solutions in the Middle East. SCI's decision to establish its state-of-the-art laboratory in Dubai Healthcare City (DHCC), the enabling healthcare and wellness destination, stems from the recognition of the region's promising growth, particularly in the United Arab Emirates and the Gulf. This strategic move positions Dubai as a central hub for stem cell banking within the Gulf Cooperation Council (GCC).

The remarkable growth witnessed in the UAE and the Gulf has motivated SCI to invest significantly in the region. The demand for advanced healthcare solutions, coupled with a thriving medical landscape, aligns seamlessly with SCI's mission to contribute to the progress of regenerative medicine.

Smart Cells International, as part of FamiCord Group, is a multinational entity with a robust presence in over 35 European countries. The group's listing on the Frankfurt Stock Market underscores its financial strength and global standing. This move to establish a GCC hub further emphasizes SCI's commitment to being a key player in the international stem cell banking arena.

Jakub Baran, Co-founder, Shareholder, and President of the Management Board of FamiCord Group, states, "Our decision to establish Dubai as the GCC hub for stem cell banking reflects our confidence in the region's potential. We aim to contribute to the advancement of healthcare in the Gulf, and this investment marks a significant milestone in our global strategy."

Shamshad Ahmed, Founder and CEO of Smart Cells International Ltd, adds, "The Gulf region's growth is undeniable, and we are excited to be a part of its healthcare evolution. Dubai's strategic location and thriving healthcare ecosystem make it an ideal choice for our stem cell banking hub. We plan to invest in clinical research partnerships and educational initiatives specific to the area to advance stem cell therapies in the region and beyond."

SCI's commitment goes beyond banking to actively contributing to the development of advanced therapies and participating in clinical trials. The establishment of the Dubai laboratory reaffirms SCI's dedication to providing cutting-edge stem cell solutions for families in the Gulf and beyond.

Smart Cells International and FamiCord Group are poised to bring their wealth of experience and expertise to the Gulf region, contributing to the transformation of healthcare through innovative stem cell solutions. The state-of-the-art Smart Cells Laboratory is located in the heart of Dubai Healthcare City, a mere 15 minutes away from Dubai International Airport. This strategic location ensures seamless transportation of samples, offering convenience and efficiency for our valued clients.

The new 4000 square foot laboratory also benefits by being equipped with cutting edge technology in the field of stem cell banking, ensuring precision and prioritizing sample safety and integrity in a fully monitored, Good Manufacturing Practice (GMP) compliant clean room. 

Allae Almanini, Chief Financial Officer, Dubai Healthcare City Authority (DHCA) said “We are pleased to welcome the newly established state-of-the-art laboratory at DHCC. This represents a major step forward in our commitment to enhancing healthcare delivery to meet the growing demands of the health sector. We acknowledge the dynamic needs of our expanding community and aim to enrich our offerings to contribute to the health sector in Dubai.”

The Dubai Smart Cells Laboratory is proud to be licensed by both the Dubai Health Authority (DHA) and Dubai Healthcare City (DHCC), demonstrating a commitment to meeting and exceeding regulatory standards. Their expertise and commitment position the Dubai Smart Cells Laboratory as a trusted partner for parents seeking to safeguard their children’s future with advanced stem cell banking.

About FamiCord Group: FamiCord Group is listed on the Frankfurt Stock Market, holds the title of No. 1 in Europe and No. 3 in the World for family stem cell banking. Operating 15 labs globally, the group has stored over 850,000 cord blood and tissue units to date, conducted 187 cord blood transplantations, treated over 4,500 patients with stem cells, and collaborates with over 1,500 hospitals around Europe. The extensive scale of operations underscores the group's serious commitment to family umbilical cord blood banking, reflecting a total market capitalization of approximately EUR 249 million, based on closing prices as of 28 May 2021.

To find out more about Smart Cells International, visit our website www.smartcells.ae